News | Biogen

October 17, 2021

Biogen Announces Topline Results from the Tofersen Phase 3 Study and its Open-Label Extension in SOD1-ALS

In the Phase 3 VALOR study, the primary endpoint as measured by the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) did not reach statistical significance; however, signs of reduced disease progression across multiple secondary and exploratory endpoints were observed The

October 14, 2021

Topline Results from Tofersen Phase 3 Study and its Open Label Extension in SOD1-ALS to be Presented at the American Neurological Association Annual Meeting

October 13, 2021

New Data at ECTRIMS 2021 Highlight Biogen’s Focus on Patient-Centered Outcomes and Improving the MS Patient Experience

List View Grid View

September 23, 2019

Interferon Beta Treatments, Including PLEGRIDY® (peginterferon beta-1a) and AVONEX® (interferon beta-1a), Receive Positive CHMP Opinion for Use During Pregnancy and Breastfeeding

Positive opinion is supported by data from more than 1,000 real-world pregnancy outcomes Data indicate no increased risk of major congenital anomalies after exposure to interferon beta before conception and/or during first trimester Data show pregnancy outcomes are in line with general population

September 18, 2019

Biogen Advances Spinal Muscular Atrophy (SMA) Clinical Research with New Study Evaluating a Higher Dose of SPINRAZA® (nusinersen) and Additional Data in a Broad Range of Patients

DEVOTE trial to evaluate safety and even greater efficacy of a higher dose of SPINRAZA in the treatment of SMA; well-established safety profile supports exploration of potential benefits Long-term data from the SHINE study demonstrate improvements in or stabilization of motor function in patients

September 17, 2019

Biogen Ranked #1 Biotechnology Company on Dow Jones Sustainability World Index

CAMBRIDGE, Mass., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that it has been ranked the #1 biotechnology company on the Dow Jones Sustainability World Index (DJSI World) for the fourth time, after being the first U.S.-based biotech company to ever make the list

September 12, 2019

New Research Demonstrate Biogen’s Continued Commitment to Improve Care of Patients with Multiple Sclerosis Across Treatment Spectrum

Data highlight benefits of TYSABRI ® (natalizumab) treatment in early multiple sclerosis for achieving NEDA (no evidence of disease activity) and improving disability and cognition An analysis of data from the TYSABRI Observational Program (TOP) demonstrates real-world effectiveness of extended

September 11, 2019

Biogen to Report Third Quarter 2019 Financials October 22,2019

Cambridge, Mass.— Biogen Inc . (Nasdaq:BIIB) today announced it will report third quarter 2019 financial results Tuesday, October 22, 2019, before the financial markets open. Following the release of the financials, the Company will host a live webcast with Biogen management from 8:00-9:00 am ET.

September 11, 2019

New Data Presented at ECTRIMS Reinforce Long-term Benefits of TECFIDERA® (dimethyl fumarate) Over 10 Years

TECFIDERA consistently maintained low levels of disease activity with no increased risk in adverse events over a decade of treatment Latest interim data from Phase 3 EVOLVE-MS-1 trial show Biogen and Alkermes’ investigational treatment, diroximel fumarate, was generally well tolerated with low

July 30, 2019

Diroximel Fumarate Demonstrated Significantly Improved Gastrointestinal Tolerability Profile Compared to Dimethyl Fumarate in Patients with Multiple Sclerosis

— Diroximel Fumarate Demonstrated Statistically Superior Gastrointestinal (GI) Tolerability on EVOLVE-MS-2 Study’s Primary Endpoint Assessing Self-Reported GI Events — — Discontinuations Due to GI Events were Less than 1% for Diroximel Fumarate — DUBLIN, Ireland and CAMBRIDGE, Mass., July 30, 2019

July 1, 2019

Biogen Announces New Data Further Establishing SPINRAZA® (nusinersen) as a Foundation of Care in Spinal Muscular Atrophy for a Broad Range of Patients

New results from the NURTURE study demonstrate that pre-symptomatic infants treated with SPINRAZA are achieving motor milestones that are unprecedented in the natural history of the disease, including 100 percent of children sitting without support and 88 percent walking independently Results add

June 19, 2019

Biogen to Report Second Quarter 2019 Financial Results July 23, 2019

Cambridge, MA , - - Biogen Inc. (Nasdaq:BIIB) today announced it will report second quarter 2019 financial results Tuesday, July 23, 2019, before the financial markets open. Following the release of the financials, the Company will host a live webcast with Biogen management from 8:00-9:00 am ET.

June 11, 2019

Biogen to Present New Safety and Efficacy Data on Biosimilars and Estimates 1.8 Billion Euros in Savings for the European Healthcare System in 2019

Data to be presented at the European Congress of Rheumatology (EULAR) 2019 highlight real-world evidence confirming the safety and efficacy of anti-TNF biosimilars and high adherence of patients to treatment Biogen’s three biosimilar treatments – BENEPALI™ (etanercept), FLIXABI™ (infliximab) and